Business Wire

IDEMIA

10.12.2020 17:47:11 CET | Business Wire | Press release

Share
IDEMIA and Kudelski IoT first-to-market with GSMA IoT-SAFE solution

IDEMIA, the global leader in Augmented Identity, and Kudelski IoT, a division of the Kudelski Group (SIX: KUD.S), the world leader in digital security and IoT solutions, today announced a joint solution for mobile network operators (MNOs), mobile virtual network operators (MVNOs), original equipment manufacturers (OEMs) and service providers to enable efficient IoT device provisioning at scale, without compromising on connectivity or data security.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005726/en/

With the growth of IoT deployments globally, the security of devices and client data stored or collected within the device has become one of the biggest concerns across the ecosystem and its users. IDEMIA, member of the Trusted Connectivity Alliance (TCA1 ), and Kudelski IoT are taking on the challenge of data privacy and device protection with a simplified, end-to-end security solution for IoT deployments designed to securely connect devices to the cloud. This solution is particularly relevant since OEMs and service providers are looking for solutions using embedded Secure Elements to protect content.

IDEMIA’s IoT SAFE solution provides the added benefit of remote management and provisioning of over-the-air (OTA) security certificates and application updates directly to the highly secure SIM environment. This also provides the ability to keep the solution up-to-date with evolving security standards.

By seamlessly integrating the Kudelski IoT Root of Trust applet and keySTREAM system within IDEMIA’s secure elements and OTA platform, OEMs, MNOs and service providers now have a solution to leverage for their own security services for their customers and end users.

The combination of IDEMIA and Kudelski’s leading positions within their respective areas of excellence ensures a simplified approach to enabling security for IoT devices and platforms, allowing plug & play installation for connected security use cases.

“The industry has been expecting standards to be defined for IoT Security. Together with GSMA and the TCA, those standards and guidelines are now in place with IoT SAFE. Thanks to our partnership with Kudelski, IDEMIA is proud to bring this technology breakthrough solution to the market. The market can now benefit from an independent technology with the added benefit of ensuring end-to-end device and data security for IoT,” said Fabien Jautard Executive Vice-President for Mobile Operators activities at IDEMIA.

“By combining IDEMIA’s Mobile Network SIMs and OTA platform with Kudelski IoT keySTREAM into a solution specifically tailored for cellular machine-to-machine communications, we bring to the market the first truly standard and dedicated end-to-end IoT security solution for mobile networks,” said Hardy Schmidbauer, SVP, Kudelski IoT.

1 TCA is a global, non-profit industry association which is working to enable a secure connected future. Its members are participants within the SIM ecosystem, which is the most widely distributed, secure application delivery platform in the world.

About IDEMIA’s Mobile Operators Business unit

IDEMIA serves clients in 180 countries and is trusted by over 500 mobile operators globally. With over 850 million SIM cards, 100 + eSIM platform references and over 2.2 eSIM consumer transactions in 2019, IDEMIA is leading the way in eSIM and remote subscription management for consumer and M2M spaces and end-to-end biometric solutions. Making MNOs the next identity providers. IDEMIA benefits from its global manufacturing footprint (Brazil, France, India and China) and cutting-edge security data centers in Europe and the United States. Our solutions are trusted by the largest Groups worldwide. Our Continuous innovation is fueled by strong R&D investments and close partnerships in IoT/M2M - Connectivity - Biometrics – Security – Encryption – QoS/QoE – Advanced SIM & services areas.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

About Kudelski IOT

Kudelski IoT is the Internet of Things division of The Kudelski Group and provides end-to-end IoT solutions, IoT product design, and full-lifecycle services to IoT device manufacturers, ecosystem creators and end-user companies. These solutions and services leverage the group’s 30+ years of innovation in digital business model creation; hardware, software and ecosystem design and testing; state-of-the-art security lifecycle management technologies and services and managed operation of complex systems. For more information about Kudelski IOT, please visit www.kudelski-iot.com .

About Kudelski Group

The Kudelski Group (SIX: KUD.S) is a world leader in digital security and a provider of end-to-end convergent media solutions to the digital entertainment industry, including services and applications requiring access control and rights management to secure the revenue in digital television, internet, mobile and interactive applications. The Group also offers cybersecurity solutions and services focused on helping companies assess risks and vulnerabilities and protect their data and systems. It also supplies integrated solutions to manage access control of people and vehicles to sites and events. The Kudelski Group is headquartered in Cheseaux-sur-Lausanne, Switzerland and Phoenix (AZ), USA. For more information, please visit www.nagra.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye